Jove
Visualize
お問い合わせ
JoVE
x logofacebook logolinkedin logoyoutube logo
JoVEについて
概要リーダーシップブログJoVEヘルプセンター
著者向け
出版プロセス編集委員会範囲と方針査読よくある質問投稿
図書館員向け
推薦の声購読アクセスリソース図書館諮問委員会よくある質問
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experimentsアーカイブ
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教員リソースセンター教員サイト
利用規約
プライバシーポリシー
ポリシー

関連する概念動画

Aneurysm III: Interprofessional Care01:26

Aneurysm III: Interprofessional Care

24
Aneurysm management involves either conservative medical therapy or surgical intervention, depending on the size and symptoms of the aneurysm. Conservative management is generally reserved for smaller, asymptomatic aneurysms, while larger or symptomatic aneurysms often necessitate surgical repair.Conservative Medical TherapyFor small, asymptomatic aneurysms, particularly abdominal aortic aneurysms (AAA) less than 5.5 centimeters in diameter, conservative medical therapy is recommended. This...
24
Angina IV: Management01:26

Angina IV: Management

22
IntroductionThe management of angina requires a comprehensive approach that includes pharmacological therapies, medical procedures, and lifestyle modifications.Pharmacological TherapiesAntiplatelet agents, such as aspirin, clopidogrel, prasugrel, and ticagrelor, play a pivotal role in preventing thrombus formation in patients with angina. These medications inhibit platelet aggregation and reduce the likelihood of myocardial infarction and other cardiovascular events.Anticoagulants, including...
22
Aortic Regurgitation III: Medical Management01:25

Aortic Regurgitation III: Medical Management

42
Aortic regurgitation (AR) is when the aortic valve does not close or seal properly, leading to backward blood circulation from the aorta into the left ventricle during diastole. Common causes of AR include rheumatic heart disease, congenital valve defects, and aortic root dilation. Managing AR requires a multifaceted approach to alleviate symptoms, preserve left ventricular function, and address the underlying cause of the regurgitation. Patients with symptomatic AR or significant left...
42
Mitral Stenosis III: Medical Management01:26

Mitral Stenosis III: Medical Management

21
Mitral stenosis, a condition marked by the narrowing of the mitral valve, necessitates an integrated approach for effective management. This approach includes preventative measures, medical therapy, and surgical interventions to reduce symptoms and prevent complications.PreventionPrevention of mitral stenosis primarily focuses on reducing the incidence of bacterial infections, particularly streptococcal infections, which can lead to rheumatic fever and subsequent valvular damage. Timely...
21
Coronary Artery Disease V: Interprofessional Care01:27

Coronary Artery Disease V: Interprofessional Care

30
Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
30
Acute Coronary Syndrome IV: Interprofessional Care01:28

Acute Coronary Syndrome IV: Interprofessional Care

26
IntroductionThe management of Acute Coronary Syndrome (ACS) aims to minimize myocardial damage, preserve myocardial function, and prevent complications.Initial ManagementInpatient management involves continuous cardiac monitoring, preferably in an ICU, focusing on blood pressure, serum sodium, potassium, and creatinine levels, and urine output. Ongoing pharmacologic management is crucial for stabilizing the patient.Supplemental Oxygen: Administer supplemental oxygen if oxygen saturation is...
26
このページは機械翻訳されています。他のページは英語で表示される場合があります。View in English
  1. ホーム
  3. 研究分野
  5. 生物医学と臨床科学
  7. 心血管医学と血液学
  9. 心臓病 (心血管疾患を含む)
  11. Angel-aspect試験の1年間の結果
  1. ホーム
  3. 研究分野
  5. 生物医学と臨床科学
  7. 心血管医学と血液学
  9. 心臓病 (心血管疾患を含む)
  11. Angel-aspect試験の1年間の結果

関連する実験動画

Optimized Management of Endovascular Treatment for Acute Ischemic Stroke
09:21

Optimized Management of Endovascular Treatment for Acute Ischemic Stroke

Published on: January 18, 2018

12.1K

ANGEL-ASPECT試験の1年間の結果

Xiaochuan Huo1, Dapeng Sun2,3, Thanh N Nguyen4

  • 1Cerebrovascular Disease Department, Neurological Disease Center, Beijing Anzhen Hospital (X.H., X.T., X.Z., S. Li), Capital Medical University, China.

Stroke
|August 25, 2025

PubMed で要約を見る

まとめ
この要約は機械生成です。

血管内療法 (EVT) は,医学的な治療 (MM) と比較して,急性性不全性脳卒中患者の1年間のアウトカムを改善しました. このアジア人群では,EVTが機能的独立性や障害の減少に持続的な利点を示しました.

キーワード:
介護者心臓発作発血性脳卒中予後について

さらに関連する動画

Fully Endoscopic Mitral Valve Repair with Percutaneous Cannulation of Groin Vessels
08:12

Fully Endoscopic Mitral Valve Repair with Percutaneous Cannulation of Groin Vessels

Published on: May 26, 2023

1.8K
Predicting Amputation using Local Circulating Mononuclear Progenitor Cells in Angioplasty-treated Patients with Critical Limb Ischemia
07:25

Predicting Amputation using Local Circulating Mononuclear Progenitor Cells in Angioplasty-treated Patients with Critical Limb Ischemia

Published on: September 22, 2020

3.5K

関連する実験動画

Optimized Management of Endovascular Treatment for Acute Ischemic Stroke
09:21

Optimized Management of Endovascular Treatment for Acute Ischemic Stroke

Published on: January 18, 2018

12.1K
Fully Endoscopic Mitral Valve Repair with Percutaneous Cannulation of Groin Vessels
08:12

Fully Endoscopic Mitral Valve Repair with Percutaneous Cannulation of Groin Vessels

Published on: May 26, 2023

1.8K
Predicting Amputation using Local Circulating Mononuclear Progenitor Cells in Angioplasty-treated Patients with Critical Limb Ischemia
07:25

Predicting Amputation using Local Circulating Mononuclear Progenitor Cells in Angioplasty-treated Patients with Critical Limb Ischemia

Published on: September 22, 2020

3.5K

科学分野:

  • 神経学
  • 介入心臓科
  • 脳卒中 医学

背景:

  • 血管内療法 (EVT) は,大型の心筋梗塞に対して90日間の効果を示しています.
  • 大量の不血症の患者で1年間のEVTと医学的管理 (MM) の結果はまだ十分に研究されていません.

研究 の 目的:

  • ANGEL- ASPECT試験におけるMMと比較して,EVTの1年間の機能的アウトカムを評価する.
  • 前部循環大血管閉塞のアジア系の大群における長期的な有効性と安全性を評価する.

主な方法:

  • 第3段階,ランダム化,オープン,ブラインドエンドポイント評価試験 (ANGEL- ASPECT).
  • 大量の不血中枢 (ASPECTS 3~5または70~100mLの心臓発作) の患者は,ランダムに1対1でEVTまたはMMに分けられました.
  • 1年後の修正ランキンスケール (mRS) の変化; 2次結果: 機能的独立性,歩行,死亡率.

主要な成果:

  • EVTは,1年後のmRS分布の改善の確率を高く示した (一般的確率比は1. 25,P=0. 04).
  • 機能的独立性 (mRS 0−2) と独立歩行能力 (mRS 0−3) は,EVTグループにおいて有意に高かった.
  • EVTの機能的独立の利点は90日から1年に縮小した.
トロンベクトミー

結論:

  • EVTは,大脳卒中および近道動脈閉塞の患者で,持続的な1年間の効果で障害を大幅に軽減します.
  • 24時間以内に発症した選択された脳卒中の患者にとって,EVTは優れた治療法である.